Evercore ISI lowered the firm’s price target on Boston Scientific (BSX) to $112 from $113 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have “set the stage for a 2026 Tools play,” the analyst tells investors. In MedTech, the firm’s survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes “have bears watching,” the analyst added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s Global Pulsed Field Ablation Trial Targets Persistent Atrial Fibrillation Growth
- Boston Scientific price target lowered to $120 from $130 at Truist
- Boston Scientific price target raised to $130 from $125 at RBC Capital
- Boston Scientific price target lowered to $131 from $132 at Canaccord
- Boston Scientific’s WATCHMAN FLX Pro Registry: A New Frontier in Atrial Fibrillation Treatment